Last of the lot

The U.S. healthcare group may buy the remaining 82 percent of Crucell it doesn t own for $2.3 bln. Big Pharma has realized the value of vaccines, and Crucell is the last big independent player. The price is stiff, but it allows J&J to deploy cash stranded overseas.